Consensus review reduces variability in assessing nuclear atypia in thyroid evaluations, suggesting improved diagnostic consistency.
Interobserver variability remains for TBS I, II, and III-other despite group review. The implementation of the two-tiered AUS will simplify our clinical practice and is expected to decrease interobserver variability in the use of AUS-nuclear atypia, which has a higher risk of malignancy.
No takes yet. Share an insight, caveat, or question.
Chen‐Yost et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: